CD8A and hepatocellular carcinoma: In addition, a report on the combination therapy of cabozantinib and anti–PD-1 antibody for hepatocellular carcinoma found that the suppression of CD8+ T-cell infiltration into tumors was ablated but there was an increase in neutrophil infiltration (28).